<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05064800</url>
  </required_header>
  <id_info>
    <org_study_id>C4671012</org_study_id>
    <nct_id>NCT05064800</nct_id>
  </id_info>
  <brief_title>PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants</brief_title>
  <official_title>A PHASE 1, OPEN-LABEL, 3-TREATMENT, 6-SEQUENCE, 3-PERIOD CROSSOVER STUDY TO ESTIMATE THE EFFECT OF PF-07321332/RITONAVIR AND RITONAVIR ON THE PHARMACOKINETICS OF DABIGATRAN IN HEALTHY PARTICIPANTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a drug-drug interaction study to assess the effects of PF-07321332/ritonavir and&#xD;
      ritonavir on the Pharmacokinetic (PK) of dabigatran in healthy volunteers. PK will be&#xD;
      evaluated for PF-07321332 and ritonavir. Dabigatran is being utilized as a P-gp substrate&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2021</start_date>
  <completion_date type="Anticipated">November 14, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 14, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a Phase1, open-label,3-treatment, 6-sequence, 3-period crossover study to estimate the effect of PF-07321332/ritonavir and ritonavir on the Pharmacokinetics of dabigatran in healthy participants</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve from time zero to infinity (AUCinf) of dabigatran when administer with PF-07321332/ritonavir</measure>
    <time_frame>Treatment A; pre-dose, and 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of dabigatran when administered with PF-07321332/ritonavir</measure>
    <time_frame>Treatment A; pre-dose, and 1, 2, 4, 6, 8, 12, 16, 24, and 48 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf of dabigatran when administered with multiple doses of ritonavir</measure>
    <time_frame>Treatment C; Pre-dose and 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of dabigatran when administered with multiple doses of ritonavir</measure>
    <time_frame>Treatment C; pre-dose and 1, 2, 4, 6, 8, 12, 16, 24, and 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Treatments A, B and C; through study completion of approximately 1.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities</measure>
    <time_frame>Treatments A, B, and C; through study completion of approximately 1.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Change From Baseline in Vital Signs</measure>
    <time_frame>Treatment A, B, and C; through study completion of approximately 1.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormalities in Physical Examination</measure>
    <time_frame>Treatment A, B, and C; through study completion of approximately 1.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Findings</measure>
    <time_frame>Treatment A, B, and C; through study completion of approximately 1.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of dabigatran</measure>
    <time_frame>Treatments A, B and C; Pre-dose and 1, 2, 4, 6, 8, 12, 16, 24, and 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2) of dabigatran</measure>
    <time_frame>Treatments A, B and C; pre-dose and 1, 2, 4, 6, 8, 12, 16, 24, and 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of PF-07321332</measure>
    <time_frame>Treatments A, B, C: pre-dose and 1, 2, 4, 6, 8, 12, 16, 24, and 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCtau (area under the curve of the dosing interval) of PF-0321332</measure>
    <time_frame>Treatments A, B and C: pre-dose and 1, 2, 4, 6, 8, 12, 16, 24, and 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of PF-0321332</measure>
    <time_frame>Treatments A, B and C: pre-dose and 1, 2, 4, 6, 8, 12, 16, 24, and 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of PF-0321332</measure>
    <time_frame>Treatments A, B and C: pre-dose and 1, 2, 4, 6, 8, 12, 16, 24, and 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Clearance (CL/F) of PF-0321332</measure>
    <time_frame>Treatments A, B and C: pre-dose and 1, 2, 4, 6, 8, 12, 16, 24, and 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) of PF-0321332</measure>
    <time_frame>Treatments A, B and C: pre-dose and 1, 2, 4, 6, 8, 12, 16, 24, and 48 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dabigatran only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-07321332/ritonavir + Dabigatran</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ritonavir + Dabigatran</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran</intervention_name>
    <description>A single dose of Dabigatran on Day 1</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-07321332/ritonavir + Dabigatran</intervention_name>
    <description>PF-07321332/ritonavir twice daily (BID) for Days 1 and 2 Single dose of Dabigatran on Day 2</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir + Dabigatran</intervention_name>
    <description>Ritonavir BID on Days 1 and 2 Single dose of Dabigatran on Day 2</description>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body Mass Index (BMI) of 17.5 to 30.5 kg.m2; and a total body weight &gt;50 kg (110 lbs)&#xD;
&#xD;
          -  Female participants must have a negative pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive test for SARS-Co-V2 at the time of screening or Day -1&#xD;
&#xD;
          -  Active pathological bleeding or risk of bleeding&#xD;
&#xD;
          -  Positive urine drug test&#xD;
&#xD;
          -  History of sensitivity to heparin or heparin induced thrombocytopenia&#xD;
&#xD;
          -  Participants who have been vaccinated for COVID-19 in the past 7 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Centers of America ( Hollywood )</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C4671012</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 1, 2021</study_first_submitted>
  <study_first_submitted_qc>September 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Drug Interaction</keyword>
  <keyword>Dabigatran</keyword>
  <keyword>P-gp Substrate</keyword>
  <keyword>SARS-Co-V2</keyword>
  <keyword>COVID-19</keyword>
  <keyword>protease inhibitor</keyword>
  <keyword>ritonavir</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

